US EditionPublished • loading... • Updated
Botensilimab/Balstilimab Exhibits Meaningful Activity in Ovarian Cancer
Summary by cancernetwork.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Deep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant population Findings reinforce the broad, pan-tumor activity of BOT+BAL across immunologically “cold” cancers LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating [.…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
